Pomerantz LLP Launches Investigation Into Omeros Corporation

The stock decline occurred on June 26, 2026, when shares of Omeros (NASDAQ: OMER) shed $2.05 to close at $8.67. This collapse followed a public disclosure that the Committee for Medicinal Products for Human Use (CHMP) had issued a negative opinion regarding the company's treatment for hematopoietic stem cell transplant-associated complications. Omeros had attempted to sway the regulatory body during an oral explanation meeting featuring four international experts, but the appeal proved unsuccessful.

Pomerantz LLP is now scrutinizing whether Omeros and its leadership engaged in unlawful business practices or misled shareholders. Investors affected by the sharp decline are encouraged to contact Danielle Peyton at the firm to discuss potential class action participation. The firm, which maintains a global presence with offices in cities including New York, Chicago, and London, specializes in securities litigation and recovering damages for corporate misconduct.